Dr. William T. Cash
Claim this profileChildren's Healthcare of Atlanta - Egleston
Expert in Neuroblastoma
Expert in Cancer
19 reported clinical trials
34 drugs studied
About William T. Cash
Education:
- Obtained an MD from the University of Alabama School of Medicine, Birmingham, Alabama.
- Holds a Bachelor of Science in Chemistry from Auburn University.
- Earned an MSc in Clinical Research from Emory University School of Medicine, Atlanta, Georgia.
Experience:
- Completed a Residency in Pediatrics at the University of Arkansas for Medical Sciences/Arkansas Children's Hospital, Little Rock, Arkansas.
- Undertook a Fellowship in Pediatric Hematology/Oncology at Emory University School of Medicine, Atlanta, Georgia.
- Serves as an Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology at Emory University.
- Appointed Medical Director for the Solid Tumor Program at the Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta.
- Acts as the Institutional Principal Investigator for the Children's Oncology Group (COG), focusing on pediatric solid tumors.
Area of expertise
1Neuroblastoma
Global LeaderStage IV
MYC positive
MYC negative
2Cancer
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials William T. Cash is currently running
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
Lorlatinib + Standard Therapy
for Neuroblastoma
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting2 awards Phase 322 criteria
More about William T. Cash
Clinical Trial Related8 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments William T. Cash has experience with
- Larotrectinib
- Palbociclib
- Erdafitinib
- Selpercatinib
- Tipifarnib
- Vemurafenib
Breakdown of trials William T. Cash has run
Neuroblastoma
Cancer
Brain Tumor
Mixed-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William T. Cash specialize in?
William T. Cash focuses on Neuroblastoma and Cancer. In particular, much of their work with Neuroblastoma has involved Stage IV patients, or patients who are MYC positive.
Is William T. Cash currently recruiting for clinical trials?
Yes, William T. Cash is currently recruiting for 5 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that William T. Cash has studied deeply?
Yes, William T. Cash has studied treatments such as Larotrectinib, Palbociclib, Erdafitinib.
What is the best way to schedule an appointment with William T. Cash?
Apply for one of the trials that William T. Cash is conducting.
What is the office address of William T. Cash?
The office of William T. Cash is located at: Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia 30322 United States. This is the address for their practice at the Children's Healthcare of Atlanta - Egleston.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.